Cell Viability
Assays Research Report: By Product (Consumables, Instruments), by Cell Type
(Human Cells, Microbial Cells, Animal cells), by Application (Stem Cell
Research & Others), End-User (Pharma Biotech Companies & Others)–
Forecast Till 2023
Market Insights:
Market Research Future (MRFR) has published a report stating that
the Cell viability Assays Industry is marked to expand at a CAGR of 9.2% during the forecast period
of 2018-2023. Increasing incidences of
individuals suffering from chronic diseases such as cancer and diabetes have induced high demand for technologically
advanced diagnosis and treatment solutions in the healthcare sector. Rise in adoption
of advanced technology in the healthcare sector and rise in prevalence of cancer and diabetes are majorly
driving the growth of the global Cell viability Assays Industry. Increasing investments in research activities for the
development of advanced healthcare solutions and high demand for
effective treatment and diagnostic techniques are some other factors that are
propelling the growth of the global Cell viability Assays Industry. However,
low penetration of advanced technology and poor healthcare facilities in the
underdeveloped regions are restraining the expansion of the global Cell
viability Assays Industry during the forecast period.
Market Segmentation:
The
global Cell viability Assays Industry has been segmented on the basis of
products, cell type, applications, and end-user. Based on products, the Cell
viability Assays Industry has been segmented into consumables and instruments.
Among these, the consumables segment has been sub-segmented into reagents,
assay kits, and microplates. The assay kits sub-segment includes tetrazolium
reduction assay kits, resazurin cell viability assays kits, calcein-Am cell
viability assays kits and others. Furthermore, the tetrazolium reduction assay
kits are classified into MIT assay kits and others. The instruments segment has
been sub-segmented into automated cell counters, flow cytometers, spectrophotometers,
and cell imaging and analysis systems.
Based on
cell type, the Cell viability Assays Industry has been segmented into human
cells, microbial cells, and animal cells. Based on applications, the Cell
viability Assays Industry has been segmented into stem cell research, clinical
and diagnostic applications, drug discovery and development, and others. Based
on end-user, the Cell viability Assays Industry has been segmented into
pharmaceutical and biotechnology companies, academic and research institutes,
hospital and diagnostic laboratories, and others.
Browse Complete Report: https://www.marketresearchfuture.com/reports/cell-viability-assays-market-6391
Regional Analysis:
The global Cell viability Assays Industry has been geographically
segmented into four major regions such as
the Americas, Asia Pacific, Europe, and the
Middle East and Africa. The Americas is forecasted to dominate the global Cell
viability Assays Industry owing to the rapid adoption of technologically
advanced diagnosis and treatment procedures in the
well-developed healthcare sector, increasing healthcare expenditure by the
population and rise in prevalence of cancer and diabetes in this region.
The Cell viability Assays Industry in the Europe region is
anticipated to expand at a significant growth rate owing to the increased
research activities for the development of advanced techniques in the
healthcare sector of this region. Increasing adoption of advanced technology in
healthcare sector for stem cell, genomics
and proteomics research activities propelling the
growth of Cell viability Assays Industry in the Asia Pacific region. The Middle
East and Africa region is projecting slow
rate of expansion in the global market owing to the low penetration of advanced
healthcare technologies in the underdeveloped areas of this region.
Industry Updates:
In September 2018, PharmaCyte Biotech, Inc., a clinical stage
biotechnology company that focuses on developing targeted cellular therapies
for treating diabetes and cancer by using its patented live-cell encapsulation
technology, Cell-in-a-Box, has announced
that it has completed the study to determine the
best assay method for accurate determination of number
of viable encapsulated cells at any given time, which will be used for treating
locally advanced, non-metastatic, inoperable cancer.
Key players:
The key
player profiled by MRFR that are operating in the global Cell viability Assays
Industry are Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, GE
Healthcare, Danaher Corporation, Becton Dickinson & Company, Promega
Corporation, Biotium, Abcam plc, Creative Bioarray, Biotek Instruments, and
PerkinElmer are some of the key players in the global Cell viability Assays
Industry.
No comments:
Post a Comment